JNM CE/SAM (January 2019): Current Treatment Strategies in Metastasized Differentiated Thyroid Cancer

JNM, January 2019, Volume 60, Number 1

Release Date: 1/1/2019
Expiration Date: 1/31/2022

SNMMI Members: Free
Non-Members: $69.00

Continuing Education Credit Information

ABNM SAM Credit
The American Board of Nuclear Medicine has reviewed and approved this Journal SAM activity submitted by the SNMMI. This activity fulfills the requirements of the ABNM Maintenance of Certification program for self-assessment. 2.0 SAMs have been awarded for this activity.

AMA-PRA (Physician)
The Society for Nuclear Medicine and Medical Imaging, Inc. (SNMMI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. SNMMI designates this enduring material for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Objectives
On successful completion of this activity, participants should be able to...
1. Judge the prognosis of patients harboring metastasized differentiated thyroid cancer.
2. Identify suitable treatment regimens considering the characteristics of the tumor and the patient’s general condition.
3. Know the basics of radioiodine treatment, tyrosine kinase (TKI) treatment, and redifferentiation treatment of metastasized DTC.


Target Audience
This article contains information of value to physicians treating patients with metastasized differentiated thyroid cancer, especially nuclear medicine physicians, medical oncologists, and endocrinologists.

Authors
Michael C. Kreissl1, Marcel J.R. Janssen2, and James Nagarajah2,3
1Department of Radiology and Nuclear Medicine, University Hospital Magdeburg, Magdeburg, Germany; 2Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands; and 3Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Duisburg, Germany


Disclosure
Dr. Kreissl has participated in advisory boards and given talks for Sanofi, Eisai, GE, AstraZeneca, Ipsen, Novartis, and Bayer Healthcare and receives research funding from GE Healthcare, AstraZeneca, Eisai, and Sanofi. In accordance with ACCME Revised Standards for Commercial Support and SNMMI Conflict-of-Interest Policy, the authors have indicated no other relevant relationships that could be perceived as a real or apparent conflict of interest. Disclosure of a relationship is not intended to suggest or to condone bias but is made to provide participants with information that might be of potential importance to their evaluation of the activity.

Contact Information

For questions please contact Lisa Dickinson, Associate Director of Education at ldickinson@snmmi.org or 703-652-6783.